• Mashup Score: 4

    Objective Ample evidence exists for the role of abnormal gut microbiota composition and increased gut permeability (‘leaky gut’) in chronic inflammation that commonly co-occurs in the gut in both obesity and diabetes, yet the detailed mechanisms involved in this process have remained elusive. Design In this study, we substantiate the causal role of the gut microbiota by use of faecal conditioned media along with faecal microbiota transplantation. Using untargeted and comprehensive approaches, we discovered the mechanism by which the obese microbiota instigates gut permeability, inflammation and abnormalities in glucose metabolism. Results We demonstrated that the reduced capacity of the microbiota from both obese mice and humans to metabolise ethanolamine results in ethanolamine accumulation in the gut, accounting for induction of intestinal permeability. Elevated ethanolamine increased the expression of microRNA- miR-101a-3p by enhancing ARID3a binding on the miR promoter. Increased m

    Tweet Tweets with this article
    • #GUTImage from the paper by Mishra et al entitled "A mechanism by which gut microbiota elevates permeability and inflammation in obese/diabetic mice and human gut" via https://t.co/kuEBftGE9K #Microbiota #Obesity https://t.co/hO91K6InFl

  • Mashup Score: 4

    Shelton et al. determine that early-life antibiotics exacerbate diet-induced obesity by disrupting interactions between the gut microbiota and the small intestine epithelium. Their study identifies that a Lactobacillus-derived metabolite, phenyllactic acid, regulates intestinal PPAR-γ to limit fat accumulation, revealing a mechanism by which the early-life microbiota protects against metabolic dysfunction.

    Tweet Tweets with this article
    • An early-life microbiota metabolite protects against obesity by regulating intestinal lipid metabolism: Cell Host & Microbe #microbiota #microbiome #obesity https://t.co/4KQOazd7RX

  • Mashup Score: 2

    Background Several randomised clinical trials (RCTs) performing faecal microbiota transplantation (FMT) for the management of inflammatory bowel disease (IBD), particularly for ulcerative colitis, have recently been published, but with major variations in study design. These include differences in administered dose, route and frequency of delivery, type of placebo and evaluated endpoints. Although the overall outcomes appear to be promising, they are highly dependent on both donor and recipient factors. Objective To develop concensus-based statements and recommendations for the evaluation, management and potential treatment of IBD using FMT in order to move towards standardised practices. Design An international panel of experts convened several times to generate evidence-based guidelines by performing a deep evaluation of currently available and/or published data. Twenty-five experts in IBD, immunology and microbiology collaborated in different working groups to provide statements on

    Tweet Tweets with this article
    • #GUTImage from the #GUTGuideline by @LRLopetuso @DeleuSara et al on "The first international Rome consensus conference on gut #microbiota and #FMT in #IBD" via https://t.co/7seMU3z08F @LGodny @h_sokol @gianluca1aniro @ibddocmaria @Iris_Dotan @alearmuzzi @GiovanniCammar9 https://t.co/xyBRuK6V1P

  • Mashup Score: 6

    Background Several randomised clinical trials (RCTs) performing faecal microbiota transplantation (FMT) for the management of inflammatory bowel disease (IBD), particularly for ulcerative colitis, have recently been published, but with major variations in study design. These include differences in administered dose, route and frequency of delivery, type of placebo and evaluated endpoints. Although the overall outcomes appear to be promising, they are highly dependent on both donor and recipient factors. Objective To develop concensus-based statements and recommendations for the evaluation, management and potential treatment of IBD using FMT in order to move towards standardised practices. Design An international panel of experts convened several times to generate evidence-based guidelines by performing a deep evaluation of currently available and/or published data. Twenty-five experts in IBD, immunology and microbiology collaborated in different working groups to provide statements on

    Tweet Tweets with this article
    • #GUTImage from the #GUTGuideline by @LRLopetuso @DeleuSara et al on "The first international Rome consensus conference on gut #microbiota and #FMT in #IBD" via https://t.co/7seMU3z08F @LGodny @h_sokol @gianluca1aniro @ibddocmaria @Iris_Dotan @alearmuzzi @GiovanniCammar9 https://t.co/8tMMWWFFXS

  • Mashup Score: 2

    There is a correlation between the intestinal microbiota and the onset of mood and memory disorders, and it is determined by the ability of the microbiota to regulate the production of neurotransmitters such as dopamine, serotonin, and norepinephrine. Inflammation of the intestinal tract, which causes the release of pro-inflammatory cytokines like TNF-alpha, IL-6, and MCP, able to pass the blood-brain barrier and affect an individual’s health and mind, is in fact one of the most reliable biologi

    Tweet Tweets with this article
    • #Blogpost: "The Role of Microbiota in Depressive Disorders" The gut microbiota significantly impacts mood and memory disorders by regulating neurotransmitter production, including dopamine, serotonin, and norepinephrine. Click here: https://t.co/qGERY1OY5m #microbiota #health… https://t.co/N3rCfL7HmH